公开(公告)号：US20230295258A1

公开(公告)日：2023-09-21

申请号：US18041392

申请日：2021-08-10

Applicant: KANAPH THERAPEUTICS INC.

Inventor： Donggeon KIM ,  Soomin RYU ,  Dahea LEE ,  Dongsu KIM ,  Jihoon CHANG ,  Byoung Chul LEE

IPC: C07K14/54 ,  C07K16/40 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K14/5434 ,  C07K16/40 ,  A61P35/00 ,  C12N15/63 ,  C07K2317/565

Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-FAP antibody is implemented in one antibody, cancer may be efficiently treated by specifically targeting FAP expressed highly in a tumor, and specifically localizing IL-2 to the tumor site. Therefore, the bispecific antibody may be utilized as a pharmaceutical composition for anticancer treatment, and thus has high industrial application potential.

公开(公告)号：US20240189306A1

公开(公告)日：2024-06-13

申请号：US18407400

申请日：2024-01-08

Applicant: KANAPH THERAPEUTICS INC.

Inventor： Miyeon KIM ,  Dohyun PARK ,  Dongsu KIM ,  Kyeongjin YOON ,  Sungpil CHOI ,  Sang Kyun LIM ,  Eu Ddeum CHUNG ,  Mijung LEE ,  Dahye JEON ,  Soyeon JANG ,  Kyungik LEE ,  Jinhwan KIM ,  Eunji KIM ,  Jieun MIN ,  Kangwoo LEE ,  Jakyung YOO

IPC: A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  A61K31/551 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D519/00

CPC classification number: A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  A61K31/551 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D519/00

Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.